An up and down week (ending down) for the market generally, due to (they say) inflation, jobs numbers, and fed interest rates. Biotech, on the other hand managed to have a more positive performance. The composite indices were up +0.3% (NASDAQ Biotech index) and +1.9% (S&P Biotech index). Again this week, the S&P Biotech did substantially better than the NASDAQ Biotech, which has not been the norm, as you can see in their YTD performances of -28% and -10% respectively.
The big winner for the week was WVE, up +41%, apparently on the announcement of a strategic collaboration with GSK, which by some analysts figures, might be worth up to $3.3 billion for WVE in milestone payments. (GSK is GlaxoSmithKline, which have deep enough pockets to make those payments). DYN’s +24% seemed in response to a number of positive analyst reports, though I’m not sure how positive the message is when the report that starts “There’s no doubt that money can be made b owing shares of unprofitable businesses." Number five for the week, CABA, up +22%, continued its gains noted in last week’s report, in response to a very successful $35 million dollar stock and warrant sale. On the other side, SNPX had a very bad week, -52%, though just before the close Friday it released a very positive report on results for a Phase 2 Clinical trail on their drug for treating advanced Alzheimer’s disease. Perhaps a more consequential loser was number five MACK, shedding -21%, most of it Friday. It is still comfortably in the number one spot YTD (+179%), though not the over +200% return of previous weeks.
This was another week when the contest portfolios couldn’t match the biotech indices, the median portfolio dropping -0.6% for the week. In the YTD performance, things tightened up considerably between first place DIEGOSAN, and coming up fast second place GENEGURU, their portfolio values now separated by less than $900. GENEGURU’s good week put them back in the black YTD. In percentage terms, RAJU_BIJLEE had the best week overall, up +13.6%. JFM WINTER should be congratulated for his return to the top ten YTD list after a 5 month absence.
Only two more reports to go. I hope everyone is having a happy, and healthy, holiday season.
|
Report Time Ranges
|
|
|
From
|
To
|
Recent
|
12/9/2022
|
12/16/2022
|
YTD
|
12/31/2021
|
Index Performance
|
|
Symbol
|
Recent
|
YTD
|
|
^IXIC
|
-2.72%
|
-31.57%
|
^NBI
|
0.27%
|
-9.99%
|
^SPSIBI
|
1.89%
|
-27.55%
|
Share Performance
|
Recent Change as % of Initial Price
|
YTD
|
Top 5
|
Bottom 5
|
Top 5
|
Bottom 5
|
WVE
|
41.401%
|
SNPX
|
-51.704%
|
MACK
|
179.28%
|
GNCA
|
-99.66%
|
DYN
|
23.549%
|
BTI.V
|
-48.148%
|
FENC
|
125.23%
|
PLXP
|
-97.63%
|
RIGL
|
22.909%
|
ACET
|
-44.997%
|
BIOA-B.ST
|
119.47%
|
CLVS
|
-97.05%
|
HROW
|
22.685%
|
PRTC
|
-21.378%
|
CBIO
|
109.85%
|
ATHX
|
-96.40%
|
CABA
|
21.900%
|
MACK
|
-20.972%
|
PCVX
|
92.52%
|
OTIC
|
-95.67%
|
Top Ten Portfolios
|
|
Top 10 Portfolio YTD
|
YTD(Portfolio - SPSIBI)
|
Rec
|
Rec(Port. - SPSIBI)
|
Rec. Change Total Value
|
DIEGOSAN
|
2.82%
|
30.37%
|
-0.87%
|
-2.760%
|
-$899.84
|
GENEGURU
|
1.94%
|
29.49%
|
4.29%
|
2.393%
|
$4189.18
|
MOPGCW
|
-9.58%
|
17.97%
|
2.73%
|
0.838%
|
$2403.32
|
TECHNETIUM
|
-19.29%
|
8.26%
|
-0.24%
|
-2.130%
|
-$192.26
|
BRENDAN_49
|
-23.97%
|
3.59%
|
3.63%
|
1.734%
|
$2661.25
|
DEW DILIGENCE
|
-25.97%
|
1.58%
|
-1.41%
|
-3.306%
|
-$1061.01
|
BMAZ001
|
-26.32%
|
1.23%
|
2.33%
|
0.440%
|
$1679.28
|
A.J. MULLEN
|
-27.54%
|
0.02%
|
0.22%
|
-1.672%
|
$159.63
|
HORSEINALFALFA
|
-27.98%
|
-0.43%
|
-1.16%
|
-3.051%
|
-$843.85
|
JFM WINTER
|
-30.08%
|
-2.53%
|
0.18%
|
-1.712%
|
$125.74
|
Average and Median Portfolio Performance
|
|
Avg Recent
|
Avg YTD
|
Median Recent
|
Median YTD
|
|
-$388
|
-37.16%
|
ARTHUR RADLEY
|
-$320
|
BIO-TITAN
|
-37.75%
|
-0.86%
|
ARTHUR RADLEY
|
-0.595%
|
|
